Blood pressure lowering efficacy of alpha blockers for primary hypertension

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2009, Pages

  Heran, Balraj S ^a   Galm, Brandon P ^b   Wright, James M ^b  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CICLETANINE; ETOZOLIN; FUROSEMIDE; INDACRINONE; LOOP DIURETIC AGENT; PIRETANIDE;

BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; URIC ACID BLOOD LEVEL;

EID: 77950177443     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004643.pub2     Document Type: Review

References (69)

1. Abraham 1985 {published data only} Abraham P A, Halstenson C E, Matzke G R, Napier J L, Keane W F. Antihypertensive therapy with once-daily administration of terazosin, a new alpha 1-adrenergic-receptor blocker. Pharmacotherapy 1985;5(5):285-9.
2. * Dauer A D. Terazosin: an effective once-daily monotherapy for the treatment of hypertension. American Journal of Medicine 1986;80(5B):29-34.
3. Deger G. Comparison of the safety and efficacy of once-daily terazosin versus twice-daily prazosin for the treatment of mild to moderate hypertension. American Journal of Medicine 1986;80(5B):62-7.
4. Deger G. Effect of terazosin on serum lipids. American Journal of Medicine 1986;80(5B):82-5.
5. Luther R R. Terazosin: a new antihypertensive agent with favorable effects on lipids. International Journal of Clinical Pharmacology, Therapy, & Toxicology 1989;27(7):313-9.
6. Luther R R, Glassman H N, Jordan D C, Sperzel W D. Efficacy of terazosin as an antihypertensive agent. American Journal of Medicine 1986;80(5B):73-6.
7. Luther R R, Glassman H N, Sperzel W D, Steinberg F J, Horton J K, Jordan D C. Terazosin: a new alpha 1-blocker for the treatment of hypertension: a review of randomized, controlled clinical trials of once-daily administration as monotherapy. Journal of Hypertension - Supplement 1986;4(5):S494- 7.
8. Luther R R, Klepper M J, Maurath C J, Glassman H N, Achari R, Laddu A R. Effects of terazosin on serum lipid levels in hypertensive blacks. Journal of Human Hypertension 1990;4(2):154-6.
9. Luther R R, Klepper M J, Maurath C J, Glassman H N, Achari R, Laddu A R. Efficacy of terazosin in the treatment of essential hypertension in blacks. Journal of Human Hypertension 1990;4(2):151-3.
10. Sperzel W D, Glassman H N, Jordan D C, Luther R R. Overall safety of terazosin as an antihypertensive agent. American Journal of Medicine 1986;80(5B):77-81.
11. Sperzel W D, Luther R R, Glassman H N. Clinical trials with terazosin. General methods. American Journal of Medicine 1986;80(5B):25-8.
12. Titmarsh S, Monk J P. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension. Drugs 1987;33(5):461-77.
13. Cubeddu 1988 {published data only} Cubeddu L X, Pool J L, Bloomfield R, Klotman P E, Pickering B I, Wombolt D G, et al.Effect of doxazosin monotherapy on blood pressure and plasma lipids in patients with essential hypertension. American Journal of Hypertension 1988;1(2):158-67.
14. Dauer 1986, Study M81-059 {published data only} * Dauer A D. Terazosin: an effective once-daily monotherapy for the treatment of hypertension. American Journal of Medicine 1986;80(5B):29-34.
15. Deger G. Comparison of the safety and efficacy of once-daily terazosin versus twice-daily prazosin for the treatment of mild to moderate hypertension. American Journal of Medicine 1986;80(5B):62-7.
16. Deger G. Effect of terazosin on serum lipids. American Journal of Medicine 1986;80(5B):82-5.
17. Luther R R. Terazosin: a new antihypertensive agent with favorable effects on lipids. International Journal of Clinical Pharmacology, Therapy, & Toxicology 1989;27(7):313-9.
18. Luther R R, Glassman H N, Jordan D C, Sperzel W D. Efficacy of terazosin as an antihypertensive agent. American Journal of Medicine 1986;80(5B):73-6.
19. Luther R R, Glassman H N, Sperzel W D, Steinberg F J, Horton J K, Jordan D C. Terazosin: a new alpha 1-blocker for the treatment of hypertension: a review of randomized, controlled clinical trials of once-daily administration as monotherapy. Journal of Hypertension - Supplement 1986;4(5):S494- 7.
20. Luther R R, Klepper M J, Maurath C J, Glassman H N, Achari R, Laddu A R. Effects of terazosin on serum lipid levels in hypertensive blacks. Journal of Human Hypertension 1990;4(2):154-6.
21. Luther R R, Klepper M J, Maurath C J, Glassman H N, Achari R, Laddu A R. Efficacy of terazosin in the treatment of essential hypertension in blacks. Journal of Human Hypertension 1990;4(2):151-3.
22. Sperzel W D, Glassman H N, Jordan D C, Luther R R. Overall safety of terazosin as an antihypertensive agent. American Journal of Medicine 1986;80(5B):77-81.
23. Sperzel W D, Luther R R, Glassman H N. Clinical trials with terazosin. General methods. American Journal of Medicine 1986;80(5B):25-8.
24. Titmarsh S, Monk J P. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension. Drugs 1987;33(5):461-77.
25. Gillenwater 1995 {published data only} Gillenwater J Y, Conn R L, Chrysant S G, Roy J, Gaffney M, Ice K, et al.Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. Journal of Urology 1995;154(1):110-5.
26. Harder 1994 {published data only} Harder S, Thurmann P. Concentration/effect relationship of bunazosin, a selective alpha 1-adrenoceptor antagonist in hypertensive patients after single and multiple oral doses. International Journal of Clinical Pharmacology & Therapeutics 1994;32(1):38-43.
27. Mersey 1984 {published data only} Dauer A D. Terazosin: an effective once-daily monotherapy for the treatment of hypertension. American Journal of Medicine 1986;80(5B):29-34.
28. Deger G. Comparison of the safety and efficacy of once-daily terazosin versus twice-daily prazosin for the treatment of mild to moderate hypertension. American Journal of Medicine 1986;80(5B):62-7.
29. Deger G. Effect of terazosin on serum lipids. American Journal of Medicine 1986;80(5B):82-5.
30. Luther R R. Terazosin: a new antihypertensive agent with favorable effects on lipids. International Journal of Clinical Pharmacology, Therapy, & Toxicology 1989;27(7):313-9.
31. Luther R R, Glassman H N, Jordan D C, Sperzel W D. Efficacy of terazosin as an antihypertensive agent. American Journal of Medicine 1986;80(5B):73-6.
32. Luther R R, Glassman H N, Sperzel W D, Steinberg F J, Horton J K, Jordan D C. Terazosin: a new alpha 1-blocker for the treatment of hypertension: a review of randomized, controlled clinical trials of once-daily administration as monotherapy. Journal of Hypertension - Supplement 1986;4(5):S494- 7.
33. Luther R R, Klepper M J, Maurath C J, Glassman H N, Achari R, Laddu A R. Effects of terazosin on serum lipid levels in hypertensive blacks. Journal of Human Hypertension 1990;4(2):154-6.
34. Luther R R, Klepper M J, Maurath C J, Glassman H N, Achari R, Laddu A R. Efficacy of terazosin in the treatment of essential hypertension in blacks. Journal of Human Hypertension 1990;4(2):151-3.
35. * Mersey J H, Elkayam U. Effect of terazosin on blood pressure and lipids in hypertension. Clinical Research 1984;32(3):668A.
36. Sperzel W D, Glassman H N, Jordan D C, Luther R R. Overall safety of terazosin as an antihypertensive agent. American Journal of Medicine 1986;80(5B):77-81.
37. Sperzel W D, Luther R R, Glassman H N. Clinical trials with terazosin. General methods. American Journal of Medicine 1986;80(5B):25-8.
38. Titmarsh S, Monk J P. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension. Drugs 1987;33(5):461-77.
39. Os 1999 {published data only} Os I, Stokke H P. Doxazosin GITS compared with doxazosin standard and placebo in patients with mild hypertension. Blood Pressure 1999;8(3):184-91.
40. * Os I, Stokke H P. Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-to-moderate hypertension. Doxazosin Investigators' Study Group. Journal of Cardiovascular Pharmacology 1999;33(5):791-7.
41. Schnaper 1975, Study 2 {published data only} * Schnaper H W, Oberman A. Double-blind studies of the clinical effectiveness of prazosin. Postgraduate Medicine 1975;Spec No: 81-7.
42. Singleton 1989 {published data only} Singleton W, Dix R K, Monsen L, Moisey D, Levenstein M, Bottiglieri D F, et al.Efficacy and safety of Minipress XL, a new once-a-day formulation of prazosin. American Journal of Medicine 1989;87(2A):45S-52S.
43. Weber 1991 {published data only} Weber M A, Cheung D G, Laddu A R, Luther R R. Antihypertensive dose-response relationships: studies with the selective alpha 1-blocking agent terazosin. American Heart Journal 1991;122(3 Pt 2):905-10.
44. Achari 2000 {published data only} Achari R, Hosmane B, Bonacci E, O'Dea R. The relationship between terazosin dose and blood pressure response in hypertensive patients. Journal of Clinical Pharmacology 2000;40:1166-72.
45. Ames 1989 {published data only} Ames R P, Chrysant S G, Gonzalez F, Schnaper H W, Spann S, Velasquez M T. Effectiveness of doxazosin in systemic hypertension. American Journal of Cardiology 1989;64(3):203-8.
46. Ames 1989a {published data only} Ames R P, Kiyasu J Y. Alpha-1 adrenoceptor blockade with doxazosin in hypertension: effects on blood pressure and lipoproteins. Journal of Clinical Pharmacology 1989;29(2):123-7.
47. Aronow 1977 {published data only} Aronow W S, Tobis J, Hughes D, Siegel J, Easthope J. Comparison of trimazosin and methyldopa in hypertension. Clinical Pharmacology & Therapeutics 1977;22(4):425-9.
48. Aronow 1978 {published data only} Aronow W S, Oberman A, Pool P E, Schnaper H W, Seagren S C, Tobis J, Hughes D, Siegel J, Easthope J. Effect of trimazosin, methyldopa, and placebo on hypertension. Current Therapeutic Research 1978;23(4):448-54.
49. Baez 1986 {published data only} Baez M A, Garg D C, Jallad N S, Weidler D J. Antihypertensive effect of doxazosin in hypertensive patients: comparison with atenolol. British Journal of Clinical Pharmacology 1986;21 Suppl 1: 63S-7S.
50. Chrysant 1981 {published data only} Chrysant S G, Miller R F, Brown J L, Danisa K. Long-term hemodynamic and metabolic effects of trimazosin in essential hypertension. Clinical Pharmacology & Therapeutics 1981;30(5):600-4.
51. Cohen 1987 {published data only} Cohen A. Placebo-controlled study of once-daily administration of terazosin to patients with mild-to-moderate hypertension. Current Therapeutic Research, Clinical & Experimental 1987;41(1):105-13.
52. Courtney 2003 {published data only} Courtney C H, McCance D R, Atkinson A B, Bassett J, Ennis C N, Sheridan B, et al.Effect of the alpha-adrenergic blocker, doxazosin, on endothelial function and insulin action. Metabolism: clinical and experimental 2003, issue 9:1147-52.
53. Gould 1981 {published data only} Gould B A, Mann S, Davies A B, Altman D G, Raftery E B. Can placebo therapy influence arterial blood pressure?. Clinical Science 1981;61 Suppl 7:487s-90s.
54. Mroczek 1974 {published data only} Mroczek W J, Fotiu S, Davidov M E, Finnerty F A Jr. Prazosin in hypertension: a double-blind evaluation with methyldopa and placebo. Current Therapeutic Research, Clinical & Experimental 1974;16(8):769-77.
55. Nash 1987 {published data only} Nash D T, Schonfeld G, Reeves R L, Black H, Weidler D J. A double-blind parallel trial to assess the efficacy of doxazosin, atenolol and placebo in patients with mild to moderate systemic hypertension. American Journal of Cardiology 1987;59(14):87G-90G.
56. Romero 1992 {published data only} Romero E, Angeli M, Velasco M, Azar E, Bueno O, Lema G, et al.Double-blind placebo-controlled trial of terazosin effect on blood pressure and urinary output of dopamine in hypertensive patients. Journal of Clinical Pharmacology 1992;32(9):816-21.
57. Smyth 1988 {published data only} Smyth P, Pringle S, Jackson G, Lorimer A R. 24-hour control of blood pressure by once daily doxazosin: a multicentre double-blind comparison with placebo. European Journal of Clinical Pharmacology 1988;34(6):613-8.
58. Svetkey 1988 {published data only} Svetkey L P, Brobyn R, Deedwania P, Graham R M, Morganroth J, Klotman P E. Double-blind comparison of doxazosin, nadolol, and placebo in patients with mild-to-moderate hypertension. Current Therapeutic Research 1988;43(5):969-78.
59. Torvik 1986 {published data only} Torvik D, Madsbu H P. Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension. British Journal of Clinical Pharmacology 1986;21 Suppl 1:69S-75S.
60. Yasunari 2006, Protocol 2 {published data only} Yasunari K, Matsui T, Maeda K, Nakamura M,Watanabe T, Kiriike N. Anxiety-induced plasma norepinephrine augmentation increases reactive oxygen species formation by monocytes in essential hypertension. American Journal of Hypertension 2006;19(6):573-8.
61. ALLHAT 2000 Davis B R, Furberg C D, Wright J T, Cutler J A, Alderman M, Black H, Cushman W, et al.Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Journal of the American Medical Association 2000;283(15):1967-75.
62. Bucher 1997 Bucher H C, Guyatt G H, Griffith L E, Walter D. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Journal of Clinical Epidemiology 1997; 50(6):683-91.
63. Cochrane Handbook 2008 Higgins J P T, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration 2008. Available from www.cochrane-handbook.org.
64. Dauer 1986 Dauer A D. Terazosin: an effective once-daily monotherapy for the treatment of hypertension. American Journal of Medicine 1986;80(5B):29-34.
65. Heran 2008a Heran BS, Wong MMY, Heran IK,Wright JM. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: CD003823. DOI:10.1002/14651858.CD003823.pub2]
66. Heran 2008b Heran BS, Wong MMY, Heran IK,Wright JM. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: CD003822. DOI: 10.1002/14651858.CD003822.pub2]
67. Musini 2008 Musini VM, Fortin PM, Bassett K, Wright JM. Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: CD007066. DOI: 10.1002/14651858.CD007066.pub2]
68. Song 2003 Song F, Altman D G, Glenny A M, Deeks J J. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. British Medical Journal 2003;326:472-76.
69. Wright 2009 Wright J M, Musini V M. First-line drugs for hypertension. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: CD001841. DOI: 10.1002/14651858.CD001841.pub2.]